drugset / Trial / NCT04821063
Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
RandomizedCrossoverQuadruple-blindTreatment
Summary
The study will evaluate the effect of a therapeutic dose and a supratherapeutic dose of ITF2357 on the QT/QTc interval.
Timeline
- Start
- 2021-04-13
- Primary completion
- 2021-06-18
- Completion
- 2021-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Givinostat | Small molecule | 100 mg | Oral |
| Subject | Givinostat | Small molecule | 300 mg | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |